कंपनी का अवलोकन
MaxCyte, Inc. operates as a life sciences company dedicated to discovering, developing, and commercializing cell therapeutics within the United States and international markets. The firm's product portfolio primarily consists of the ExPERT ATx, which serves as a static electroporation instrument designed for small to medium-scale transfection applications. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, where it focuses on advancing technologies for cellular manipulation and treatment. The company currently maintains a market capitalization of $81.21 million, supported by an annual revenue stream of $33.03 million and a workforce of 91 employees. These valuation and revenue figures indicate that MaxCyte occupies a niche position in the medical device landscape, reflecting a smaller market footprint relative to large-cap healthcare peers but maintaining active commercialization efforts in specialized biotechnology applications.
वित्तीय स्वास्थ्य
The company reported trailing twelve-month revenue of $33.03 million, yet recorded a net income of -$44,630,000 and an EBITDA of -$40,222,000. The substantial disparity between positive revenue and negative net income reveals a significant cost structure burden, likely driven by high research and development expenses or operational costs that exceed gross profitability. Free cash flow stands at -$15,469,750, indicating that the company is currently consuming cash rather than generating liquidity, which limits its financial flexibility for capital expenditures or unexpected obligations. Despite the negative operating margin of -94.8% and a profit margin of -135.1%, the firm retains an impressive gross margin of 81.2%, suggesting that its core product sales are highly profitable before accounting for significant selling, general, and administrative expenses. The balance sheet shows a cash reserve of $103.04 million against total debt of $17.94 million, resulting in a debt-to-equity ratio of 10.46, which presents a complex picture of high leverage relative to equity but substantial cash coverage. A current ratio of 8.30 demonstrates robust short-term liquidity, as the company holds assets sufficient to cover its current liabilities more than eight times over. Return on equity is calculated at -23.6% and return on assets at -12.6%, metrics that reveal management has not yet achieved positive returns on shareholder capital or the asset base, reflecting the early-stage nature of the business model.
मूल्यांकन आकलन
MaxCyte, Inc. presents a trailing P/E ratio that is effectively unavailable due to negative earnings, while the forward P/E is listed as -2.83, implying that the market prices the stock based on future expectations rather than current profitability. The price-to-book ratio is 0.47, indicating that the market values the company at less than half of its net book value, which suggests a deep discount relative to the underlying equity recorded on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 2.46 and an EV/EBITDA of 0.10 provide insight into the company's pricing relative to its revenue generation and earnings power, respectively, despite the negative earnings profile. The stock has traded between a 52-week high of $2.96 and a 52-week low of $0.64, with current trading levels situated within this historical range but significantly below the recent highs. The beta value of 1.45 indicates that the stock exhibits higher volatility than the broader market, meaning price fluctuations for MXCT are amplified compared to the overall index movements.
Growth & Income
The company experienced a year-over-year revenue decline of -16.0%, while earnings growth is marked as N/A due to the lack of positive earnings data for comparison. Since earnings are negative, they are not growing faster than revenue in a traditional sense, but rather the firm is operating at a loss while managing revenue contraction, which implies challenges in scaling operations or maintaining market share. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute income to shareholders and instead retains all available cash to fund operations and future growth initiatives. The overall growth and income profile for MaxCyte is characterized by revenue contraction, negative earnings growth, and a total absence of dividend distributions, highlighting a capital-intensive growth strategy that relies on internal funding rather than shareholder returns.